Comparable stake leader
ORAMED PHARMACEUTICALS INC.
SEC ownership of Lifeward Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001607962.
Disclosed value leader
Lind Global Fund II LP
Comparable rows
3/35
Latest evidence
01 May 2026
- Public ticker
- LFWD on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORAMED PHARMACEUTICALS INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 35
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORAMED PHARMACEUTICALS INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001607962
- Issuer location
- Hudson, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Lifeward Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORAMED PHARMACEUTICALS INC.
Disclosed value leader
Lind Global Fund II LP
Comparable rows
3/35
Latest evidence
01 May 2026
3/4/5
13D/G
13F
Lead comparable stake: 50%
32 rows are not safely comparable across share classes.
13D/G row: ORAMED PHARMACEUTICALS INC.
Showing 1-8 of 35 holder rows.
Quick read
ORAMED PHARMACEUTICALS INC. leads the comparable SEC ownership view at 50%.
3 of 35 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORAMED PHARMACEUTICALS INC.'s linked filing trail.
Comparable ownership
Top 3
ORAMED PHARMACEUTICALS INC.
50%
INTRACOASTAL CAPITAL, LLC
5%
Lind Global Fund II LP
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 35 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. |
3/4/5
13D/G
10%+ Owner
|
50%
from 13D/G
|
$800,232
1,250,363 shares
|
— | 25 Mar 2026 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
—
819,443 shares
|
$0 | 25 Jun 2025 |
| Lind Global Fund II LP |
3/4/5
13D/G
10%+ Owner
|
1.7%
from 13D/G
|
$2,308,009
857,996 shares
|
— | 06 Jan 2025 |
| Michael A. Lawless |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$295,687
464,914 shares
mixed-class rows
|
— | 23 May 2024 |
| Ori Gon |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$176,136
241,282 shares
|
— | 30 Jun 2021 |
| Jeff Dykan |
3/4/5
Director
|
—
class O/S missing
|
$171,413
234,812 shares
|
— | 13 Sep 2023 |
| Charles Remsberg |
3/4/5
Chief Sales Officer
|
—
class O/S missing
|
$146,000
200,000 shares
|
— | 11 Aug 2023 |
| Lawrence J. Jasinski |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$127,545
208,986 shares
mixed-class rows
|
— | 21 May 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,018.
Buys
$0
Insiders: 0
Sells
$1,018
Insiders: 1
Net
-$1,018
Shares: -1,591
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 1,591
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 1,591 | $0 | $1,018 | -$1,018 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to Lifeward Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Lind Global Fund II LP
Net 12M change
-$1,018
Latest report
01 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lind Global Fund II LP | 10%+ Owner | $2,308,009 | Filing P/S | 06 Jan 2025 | ||
| ORAMED PHARMACEUTICALS INC. | 10%+ Owner | $800,232 | Mixed | 25 Mar 2026 | ||
| Michael A. Lawless | Chief Financial Officer | $295,687 | Mixed | 23 May 2024 | ||
| Ori Gon | Chief Financial Officer | $176,136 | Mixed | 30 Jun 2021 | ||
| Jeff Dykan | Director | $171,413 | Mixed | 13 Sep 2023 | ||
| Charles Remsberg | Chief Sales Officer | $146,000 | Mixed | 11 Aug 2023 | ||
| Lawrence J. Jasinski | Chief Executive Officer, Director | $127,545 | Mixed | 21 May 2025 | ||
| Keith Dale Rose | Chief Medical Officer | $113,238 | Median | 01 May 2026 | ||
| Joseph E. Turk Jr. | Director | $76,629 | Mixed | 01 Aug 2025 | ||
| Michael Swinford | Director | $73,700 | Mixed | 01 Aug 2025 | ||
| Yasushi Ichiki | Director | $58,871 | Mixed | 02 Aug 2022 | ||
| Yohanan Engelhardt | Director | $58,827 | Mixed | 02 Aug 2022 | ||
| Aryeh Dan | Director | $51,875 | Mixed | 15 Aug 2023 | ||
| Jeannine Lynch | VP of Market Access & Strategy | $49,954 | -$1,018 | -2% | Mixed | 11 Dec 2025 |
| Randel Richner | Director | $41,965 | Mixed | 01 Aug 2025 | ||
| John William Poduska Sr. | Director | $40,845 | Mixed | 01 Aug 2025 | ||
| Hadar Levy | Director | $37,650 | Mixed | 01 Aug 2025 | ||
| Wayne Weisman | Director | $36,500 | Mixed | 02 Aug 2022 | ||
| Robert J. Marshall Jr. | Director | $26,221 | Mixed | 01 Aug 2025 | ||
| Moshe H. Rozenbaum | Director | $6,622 | Mixed | 25 Mar 2026 |
Recent insider transactions for Lifeward Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Keith Dale Rose | LFWD | Ordinary Shares, no par value per share | Award | 720.1% | 15,000 | 17,083 | 01 May 2026 | Direct | ||
| William Mark Sigsbee | LFWD | Ordinary Shares, no par value per share | Award | 11,485 | 11,485 | 25 Mar 2026 | Direct | |||
| Moshe H. Rozenbaum | LFWD | Ordinary Shares, no par value per share | Award | 11,485 | 11,485 | 25 Mar 2026 | Direct | |||
| Almog Adar | LFWD | Option (Right to Buy) | Award | 39,934 | 39,934 | 25 Mar 2026 | Direct | |||
| William Mark Grant | LFWD | Option (Right to Buy) | Award | 172,698 | 172,698 | 25 Mar 2026 | Direct | |||
| Yehuda Reznick | LFWD | Ordinary Shares, no par value per share | Award | 7,657 | 7,657 | 25 Mar 2026 | Direct | |||
| Nadav Kidron. | LFWD | Ordinary Shares, no par value per share | Award | 7,657 | 7,657 | 25 Mar 2026 | Direct | |||
| Miriam Kidron. | LFWD | Ordinary Shares, no par value per share | Award | 7,657 | 7,657 | 25 Mar 2026 | Direct | |||
| Jeannine Lynch | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 108.5% | 50,000 | 96,067 | 11 Dec 2025 | Direct | ||
| Jeannine Lynch | LFWD | Ordinary Shares, par value NIS 1.75 per share | Sale | -3.34% | $1,018 | $0.6400 | -1,591 | 46,067 | 02 Sep 2025 | ESOP |
| Almog Adar | LFWD | Option (Right to Buy) | Award | 225,000 | 225,000 | 13 Aug 2025 | Direct | |||
| Randel Richner | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 166.6% | 35,920 | 57,487 | 01 Aug 2025 | ESOP | ||
| Hadar Levy | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 229.4% | 35,920 | 51,576 | 01 Aug 2025 | ESOP | ||
| Joseph E. Turk Jr. | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 491.4% | 71,839 | 86,457 | 01 Aug 2025 | ESOP | ||
| John William Poduska Sr. | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 179.3% | 35,920 | 55,953 | 01 Aug 2025 | ESOP | ||
| Robert J. Marshall Jr. | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 35,920 | 35,920 | 01 Aug 2025 | Direct | |||
| Michael Swinford | LFWD | Ordinary Shares, par value NIS 1.75 per share | Award | 357.8% | 35,920 | 45,960 | 01 Aug 2025 | ESOP |
* marks a reported price that did not pass the local price check.